ProMetic Life Sciences Inc. (TSE:PLI)’s share price shot up 12.5% during trading on Monday . The company traded as high as C$0.05 and last traded at C$0.05. 1,897,802 shares were traded during mid-day trading, a decline of 29% from the average session volume of 2,661,270 shares. The stock had previously closed at C$0.04.
A number of research firms have recently commented on PLI. Canaccord Genuity downgraded ProMetic Life Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 23rd. Royal Bank of Canada cut their price objective on ProMetic Life Sciences from C$1.25 to C$0.70 and set an “outperform” rating on the stock in a report on Wednesday, April 3rd. Echelon Wealth Partners downgraded ProMetic Life Sciences from a “speculative buy” rating to a “hold” rating in a report on Tuesday, April 2nd. Finally, National Bank Financial upgraded ProMetic Life Sciences from an “underperform market weight” rating to a “sector perform market weight” rating in a report on Monday, March 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of C$0.43.
The firm has a market capitalization of $828.82 million and a P/E ratio of -0.15. The company has a quick ratio of 0.77, a current ratio of 1.14 and a debt-to-equity ratio of 238.62.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://dakotafinancialnews.com/2019/05/15/prometic-life-sciences-pli-shares-up-12-5.html.
ProMetic Life Sciences Company Profile (TSE:PLI)
Prometic Life Sciences Inc operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals.
Featured Article: Calculating net profit and net profit margin ratio
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.